Oxford Technology Management Limited, founded in 1983 and based in Oxford, United Kingdom, is a venture capital firm that focuses on investing in startup and early-stage technology-based businesses with significant growth potential. The firm primarily targets unlisted companies within a 60-mile radius of Oxford, emphasizing sectors such as science, technology, engineering, healthcare, and information technology. Oxford Technology Management typically invests between £0.1 million and £0.5 million in initial funding, with the potential for additional investments of up to £2 million in subsequent funding rounds. The investment strategy aims to allocate approximately half of the funds to early-stage companies that have achieved initial sales, while the remainder is directed towards earlier-stage startups. The team at Oxford Technology Management consists of professionals with scientific and engineering backgrounds, ensuring a strong understanding of the technologies underpinning their investments.
Mach42 is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation.
Gripable develops digital therapy tools, combining them with mobile games, and motivating physically impaired patients. GripAble began during our research with stroke patients struggling to use their hands for simple activities. Everyday tasks - getting dressed in the morning, holding a glass of water - are a huge frustration for them. This is the reality for over 500 million people around the world suffering from impaired arm mobility. These patients need, and want, more therapy. GripAble's first product is a highly sensitive, portable hand-grip that connects wirelessly with a mobile-based app, allowing patients to play our fun therapy games. It is designed for low-cost, easy-access assessment and therapy of the hand and arm disability, providing increased engagement and allowing for self-training in hospitals and at home.
Oxwash is a provider of sustainable on-demand laundry and wet and dry cleaning services for all. It uses a combination of electric cargo bikes as well as its own fleet of electric vans and DPDs electric vehicle service for a nationwide zero-emission logistics footprint. The company's aim is for clinically-clean, net zero carbon emissions for the whole process, from the collection, through washing and back to delivery. Oxwash was founded by Dr. Kent Grant in 2018 and is based in Oxford, United Kingdom.
Curileum Discovery is a biotechnology company in London discovering and developing novel therapeutics to intervene early in the development of severe GI diseases. ULI-015 is a novel small molecule that the company's scientists discovered that redirects precancerous cell production in polyps to healthy tissues. Daily oral treatment profoundly reduced polyps after three months in a porcine bowel cancer model (255 necrotic polyps, 1 progressive polyp). After six months, polyps regressed and fused with healthy tissue (571 regressed polyps, 1 progressive polyp). The company has developed a large scale, one-step method to isolate gram levels of ULI-015 from a plant source. The company anticipates obtaining Orphan Drug Designation to test ULI-015 in familial adenomatous polyposis (FAP) patients. Curileum is based at St Mark’s Hospital in London, Europe’s oldest and largest registry of FAP patients. ULI-015 will target the large sporadic bowel cancer market by treating high-risk individuals identified in bowel screening programmes. Curileum is fundraising to advance ULI-015 to clinical PoC.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered
Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered
Bodle Technologies is developing SRD®, the world’s first solid-state reflective display technology, based on phase-change materials. Providing vivid colour and video-capability, with zero energy use for static image storage, the technology is ideally suited to address the issues of poor outdoor readability and high power consumption associated with transmissive and emissive displays
Gripable develops digital therapy tools, combining them with mobile games, and motivating physically impaired patients. GripAble began during our research with stroke patients struggling to use their hands for simple activities. Everyday tasks - getting dressed in the morning, holding a glass of water - are a huge frustration for them. This is the reality for over 500 million people around the world suffering from impaired arm mobility. These patients need, and want, more therapy. GripAble's first product is a highly sensitive, portable hand-grip that connects wirelessly with a mobile-based app, allowing patients to play our fun therapy games. It is designed for low-cost, easy-access assessment and therapy of the hand and arm disability, providing increased engagement and allowing for self-training in hospitals and at home.
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
Curileum Discovery is a biotechnology company in London discovering and developing novel therapeutics to intervene early in the development of severe GI diseases. ULI-015 is a novel small molecule that the company's scientists discovered that redirects precancerous cell production in polyps to healthy tissues. Daily oral treatment profoundly reduced polyps after three months in a porcine bowel cancer model (255 necrotic polyps, 1 progressive polyp). After six months, polyps regressed and fused with healthy tissue (571 regressed polyps, 1 progressive polyp). The company has developed a large scale, one-step method to isolate gram levels of ULI-015 from a plant source. The company anticipates obtaining Orphan Drug Designation to test ULI-015 in familial adenomatous polyposis (FAP) patients. Curileum is based at St Mark’s Hospital in London, Europe’s oldest and largest registry of FAP patients. ULI-015 will target the large sporadic bowel cancer market by treating high-risk individuals identified in bowel screening programmes. Curileum is fundraising to advance ULI-015 to clinical PoC.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time. The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics is based in Oxford in the UK. For more information please visit: www.oxsonics.com.
Electrowinning Technologies has a method for controlling the very large currents which are used in metal winning operations. By controlling these currents, electrowinning plants would improve both the quality and the quantity of the metals produced and would also reduce energy consumption. There are also applications in electrorefining, the main copper refining method used in Europe.
Curileum Discovery is a biotechnology company in London discovering and developing novel therapeutics to intervene early in the development of severe GI diseases. ULI-015 is a novel small molecule that the company's scientists discovered that redirects precancerous cell production in polyps to healthy tissues. Daily oral treatment profoundly reduced polyps after three months in a porcine bowel cancer model (255 necrotic polyps, 1 progressive polyp). After six months, polyps regressed and fused with healthy tissue (571 regressed polyps, 1 progressive polyp). The company has developed a large scale, one-step method to isolate gram levels of ULI-015 from a plant source. The company anticipates obtaining Orphan Drug Designation to test ULI-015 in familial adenomatous polyposis (FAP) patients. Curileum is based at St Mark’s Hospital in London, Europe’s oldest and largest registry of FAP patients. ULI-015 will target the large sporadic bowel cancer market by treating high-risk individuals identified in bowel screening programmes. Curileum is fundraising to advance ULI-015 to clinical PoC.
Lupe Technology is a consumer technology designed to take cordless vacuum cleaning suction power. They design cordless vacuum cleaners. Their vacuum cleaner includes a motorized agitator with a rotating seal that surfaces for cleaning hair and deep-down dirt equipped with a removable battery pack that enables users to clean their houses.
Active Needle Technology is an early-stage innovative medical device company dedicated to transforming treatment pathways through accurate image-guided interventional radiology. The company has a proprietary medical device platform technology for the accurate imaging and placement of needles in vivo. The technology represents a significant improvement over currently available technologies benefiting patients, clinicians and health-care providers.
Molecular Warehouse develops proteins for diagnostics and therapeutics. The company was incorporated in 2015 and is based in Twickenham, United Kingdom.
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
Orbit Discovery is a peptide display company identifying potential peptide drugs for a range of chronic diseases. Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. They are, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Their technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development
Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model.
Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation.
SIME is a clinical AI platform company committed to preventative, personalized point-of-care medicine. Their solutions provide data-driven and precise insights to doctors in decisive moments, when rapid intervention can save a life. Developed by world-renowned scientists and doctors, their data engine detects disease in real-time, enabling early treatment in high-risk patients. The first urgent unmet needs that we are addressing are in the neonatal intensive care unit; where our clinically proven, and patented technologies will have the greatest impact. Through curation and analysis, their AI platform generates unique datasets which can be used by SIME to discover new products, or by third-party commercial partners in all areas of medicine. SIME is a London (UK), Copenhagen (Denmark), and Shanghai (China) based company with over three decades of experience of pioneering innovation in medicine and data science.
The Sasets project and asset management software service platform has been designed to take advantage of the efficiencies offered by the latest cloud computing and software application models. The service resides on Microsoft Azure a global leading cloud computing platform which has been developed to be secure, enterprise scalable, and is capable of being deployed globally. Our solution improves employee productivity and organisational processes in the workplace, by delivering industry specific business applications to the construction industry. Evidence shows that vertical SaaS solutions are delivering 20% to 50% performance gains in similar market sectors where they have replaced traditional solutions.
It specialises in location based marketing solutions to help brands improve customer relationships and loyalty. Founded in 2013 by Thomas Young, the company has grown strength to strength working with some of the biggest brands to name.
Designer Carbon Materials Ltd is developing advanced nanomaterials for a range of applications, including energy harvesting, bio-sensing and quantum nanoelectronics. We are producing designer endohedral fullerene molecules with tailored electronic properties. Designer Carbon Materials Ltd is a spin-out company from the University of Oxford. It is based on research led by Dr Kyriakos Porfyrakis and his academic group of 9 researchers. Dr Porfyrakis has been developing methods for the synthesis and chemical functionalization of endohedral fullerenes for over 12 years. Designer Carbon Materials Ltd has licensed the intellectual property portfolio developed by Dr Porfyrakis and his group.
Run3D provides an accurate and objective assessment of your biomechanics in order to understand the root-cause of injury and provide you with an evidence-based, long-term solution to the problem. Our expertly trained clinicians take scientific measures of your 3D gait biomechanics, muscular strength, flexibility and alignment and use the information to create a personalised and effective rehabilitation programme. We are a spin-out from the University of Oxford and use a state-of-the art 3D motion capture system and the world's largest biomechanical database to offer you the most rigorous assessment of your running or walking injury that is currently available. Run3D is partnered with the world-leaders in 3D gait analysis - the Running Injury Clinic at the University of Calgary. Together we are proudly leading the way in our evidence-based approach to musculoskeletal overuse injuries.
Organic LED (OLED) displays represent the most promising new display technology to have emerged in the past 20 years; more efficient, powerful and cleaner than the prevailing LED, LCD and Plasma standards. OLEDs offer enhanced performance in terms of response time, viewing angle, contrast ratio and flexibility, and environmental advantages, with low power consumption, fewer materials, longer lifetime and no requirement for a backlight to drive them. Power OLEDs is at the forefront of developing world-class, high performance hole transporters, electron transporters, electron injectors, host and emitters for selected global manufacturers. Led by a strong team with over 60 years combined experience in the OLED space, the company holds a wide IP estate and a strong pipeline of new materials. Licensed to Japanese manufacturer in 2019.
Combat Medical are a Spanish company that have developed a new treatment for bladder cancer, and are planning to start the business in the UK. The current treatment for bladder cancer involves surgery to cut the tumours out. This treatment results in a 78% recurrence rate, and so calls for more and more surgery. Combat Medical's treatment involves heating up chemotherapy chemicals and circulating them around the bladder. It currently boasts a recurrence rate of less than 20% - a marked improvement. It also offers great cost savings, as there is less of a chance of having to perform additional surgeries.
It specialises in location based marketing solutions to help brands improve customer relationships and loyalty. Founded in 2013 by Thomas Young, the company has grown strength to strength working with some of the biggest brands to name.
Metal Powder & Process
Seed Round in 2013
Metal Powders & Process is seeking to build an atomiser that will produce metal powders is high volumes, with no impurities. The hope is that this will allow more industries to begin using metal powders to craft their components. Currently, contaminants in metal powders cause weak points in components, which are negligible for most purposes, but unusable under high stress in environments such as Aerospace.
Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation.
IBEXIS TECHNOLOGIES is a leading provider of innovative sensory networking, remote data acquisition, monitoring and control products, systems and solutions. We have clients in a variety of industries including the Environmental, Building and Construction, Energy and Industrial sectors and they utilise our expertise to: Increase Customer Satisfaction Levels Significantly Reduce Operational Costs Improve Health and Safety in the Work Place Lower their Organisation’s Carbon Footprint Execute their CSR Strategies Ensure Regulatory Compliance Capable of supporting a variety of lead industry specific protocols, our solutions are used to remotely monitor and control industrial equipment (e.g. HMI’s and PLCs), sensors, probes as well as management and supervisory systems. Having an open systems approach enables our solutions to not only readily integrate into existing customer environments, but also extends (and often enhances) the capability of on-site systems to remote users who can securely access, control and monitor such systems using their laptop or smart device and also receive any relevant warnings and alerts. Our product and services portfolio is comprised of our IM SERIES Hardware and Systems product range, Enterprise Monitoring Software Suite, Managed Services, System Integration Services and Hardware and Software Product Development expertise.
It specialises in location based marketing solutions to help brands improve customer relationships and loyalty. Founded in 2013 by Thomas Young, the company has grown strength to strength working with some of the biggest brands to name.
Combat Medical are a Spanish company that have developed a new treatment for bladder cancer, and are planning to start the business in the UK. The current treatment for bladder cancer involves surgery to cut the tumours out. This treatment results in a 78% recurrence rate, and so calls for more and more surgery. Combat Medical's treatment involves heating up chemotherapy chemicals and circulating them around the bladder. It currently boasts a recurrence rate of less than 20% - a marked improvement. It also offers great cost savings, as there is less of a chance of having to perform additional surgeries.
One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects. Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals. MOTI1001 is BioMoti’s lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.
Run3D provides an accurate and objective assessment of your biomechanics in order to understand the root-cause of injury and provide you with an evidence-based, long-term solution to the problem. Our expertly trained clinicians take scientific measures of your 3D gait biomechanics, muscular strength, flexibility and alignment and use the information to create a personalised and effective rehabilitation programme. We are a spin-out from the University of Oxford and use a state-of-the art 3D motion capture system and the world's largest biomechanical database to offer you the most rigorous assessment of your running or walking injury that is currently available. Run3D is partnered with the world-leaders in 3D gait analysis - the Running Injury Clinic at the University of Calgary. Together we are proudly leading the way in our evidence-based approach to musculoskeletal overuse injuries.
Acunu Analytics offers a platform for low-latency, continuous analytics on big data; powering dashboards and embedded applications to monitor and control environments in manufacturing, telecommunications, media, financial services and other industries where high-velocity data must be analysed in real time. The Cassandra NoSQL database is at the core of the Acunu offering and Acunu is a very engaged Cassandra contributor donating many of its innovations back to the community. Acunu was founded in 2009 and is backed by some of Europe’s top VC funds. Started by a unique mix of researchers and engineers from Cambridge and Oxford Universities, Acunu has offices in London (near Old Street, London’s “Silicon Roundabout”) and California.
Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model.
Select Technology is a design and engineering company, provides software solutions for the copier and multi-function device industry. It offers PaperCut MF, a print, copy, fax, and scan management solution; KPAX Manage, a print fleet management solution for resellers; Presto, which enables users to publish existing Windows print queues to iOS device; EveryonePrint, a mobile print solution; Drivve Image, a scanning software; and selectSCAN, a scanning and capture solution for employees.
Orthogem develops and manufactures synthetic bone grafts. Its patented Tripore technology platform has enabled the creation of a pipeline of SBG's formulated for a variety of clinical applications, ranging from spinal to oral cranial facial surgery. Orthogem's products include TriPore Granules, TriPore MPA, and TriPore Blocks. Wei Lo founded it in 2001, with its headquarters in Nottingham in the United Kingdom.
Crysalin was founded in June 2007 to research and develop crysalin lattice technology derived from patented work conducted since 2002 in the Oxford University Laboratory of Molecular Biophysics. Crysalins are a protein-based nanotechnology with proven application in protein structure determination. Crysalins demonstrate significant advantages over other methodologies for protein structure determination since they are able to impose order on macromolecular targets to enable X-ray and EM instruments to resolve 3-D molecular structure where current technologies have failed (in particular: membrane proteins, soluble proteins with flexible regions). Crysalins also have the potential for use in biosensor development and optoelectronics.
Acunu Analytics offers a platform for low-latency, continuous analytics on big data; powering dashboards and embedded applications to monitor and control environments in manufacturing, telecommunications, media, financial services and other industries where high-velocity data must be analysed in real time. The Cassandra NoSQL database is at the core of the Acunu offering and Acunu is a very engaged Cassandra contributor donating many of its innovations back to the community. Acunu was founded in 2009 and is backed by some of Europe’s top VC funds. Started by a unique mix of researchers and engineers from Cambridge and Oxford Universities, Acunu has offices in London (near Old Street, London’s “Silicon Roundabout”) and California.
LabMinds is the leader in AI and robotics for solution preparation in pharmaceutical and life science labs. A cornerstone of R&D and QA/QC processes, solution preparation continues to be a highly manual process with many moving parts, exposing labs to considerable risk and inevitable waste. LabMinds’ platform addresses these challenges with powerful AI software combined with state-of-the-art robotics to safeguard against tainted inputs, enable near-perfect accuracy, and attain unmatched control. Further, labs in the LabMinds network contribute to, and benefit from, the collection of input and sensor data throughout the solution prep process; it’s never been easier to gain detailed insight into how chemicals interact with each other. By implementing more security and order, and leveraging the power of big data, LabMinds moves ever closer to achieving its mission to enable scientists and businesses to build and optimize labs, in order to bring meaningful therapies to market sooner.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.
Base4 is focused on the innovation and development of state-of-the-art technologies for single-molecule analysis. We are developing cutting-edge, high-value technologies with demonstrable technical and commercial feasibility while building a valuable portfolio of IP and know-how.
Diamond Microwave Devices Ltd. engages in the development of semiconductor devices based on CVD diamond. Its devices are used in civil and defense systems for microwave power amplifier and transmitter applications. The company was founded in 2006 and is based in Leeds, the United Kingdom. Diamond Microwave Devices Ltd. operates as a subsidiary of Element Six (Pty) Ltd.
Acunu Analytics offers a platform for low-latency, continuous analytics on big data; powering dashboards and embedded applications to monitor and control environments in manufacturing, telecommunications, media, financial services and other industries where high-velocity data must be analysed in real time. The Cassandra NoSQL database is at the core of the Acunu offering and Acunu is a very engaged Cassandra contributor donating many of its innovations back to the community. Acunu was founded in 2009 and is backed by some of Europe’s top VC funds. Started by a unique mix of researchers and engineers from Cambridge and Oxford Universities, Acunu has offices in London (near Old Street, London’s “Silicon Roundabout”) and California.
Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model.
OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
Mirriad’s award-winning solution unleashes new revenue for content producers and distributors by creating new advertising inventory in content. Our patented, AI and computer vision technology dynamically inserts products and innovative signage formats after content is produced. Mirriad’s market-first solution seamlessly integrates with existing subscription and advertising models, and dramatically improves the viewer experience by limiting commercial interruptions. Mirriad currently operates in the US, Europe and China.
Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.
Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Pharma Engineering Ltd
Venture Round in 2007
Pharma Engineering has developed and patented a gentle method to remove tablets and capsules from blister packs without damaging them. The pharmaceutical industry is large and manufactures billions of blister-packaged tablets. It is common for 2-6% of this manufactured product to be stopped for quality reasons relating to the packaging. Recovering these tablets so that they can be re-packaged can yield easy savings.
Oxtox is developing Drugsensorâ„¢, a device that uses novel and cost-effective technology to rapidly detect whether a person is currently 'under the influence' of specific drugs, all with a minimum of inconvenience.
Incentec Ltd
Venture Round in 2006
Incentec Ltd has been developing a predictive diagnostic for pre-eclampsia, a poorly defined condition affecting approximately 6% of first pregnancies. The causes of pre-eclampsia are unknown, although a failure in placental development is thought to be a factor. There is no diagnostic test currently in use and at the moment, at-risk patients (or suspected cases of pre-eclampsia) are monitored and treated on the basis of observable and developing clinical symptoms.
Imagineer Systems Limited offers research, development, and marketing services for visual effects solutions in film, video, and broadcast post production. Its products include monet, a tracking and compositing toolset and mokey, a toolset for removing wires, rigs, logos, scratches, and hairs for commercial, film, and corporate video post production. Additionally, the company provides mocha, a 2D tracking and rotoscoping tool that generates position, scale, rotation, shear, and perspective matched tracks for special effects in film and video production. Imagineer Systems also offers virtual product placement, lens distortion correction, noise reduction, grain management, and keying tools. Imagineer Systems Limited was founded in 2000 and is based in Guildford, United Kingdom.
Dexela develops a 3-D breast imaging technology for the early detection of breast cancer. It offers DexTop Digital Mammography Workstation, a screening workstation that ensures screening workflow and performance; and Dexela 3D reconstruction engine that is offered to OEM partners as a software module with licensing terms. The company provides flat panel CMOS X-ray detectors that are used in various medical applications, including mammography and tomosynthesis, breast CT, dental CBCT, fluoroscopy, cardiology and angiographic imaging, and bone densitometry, as well as in scientific instrumentation and non-destructive testing applications. It also offers consulting services in the areas of digital tomosynthesis, mammography acquisition geometry, and optimal reconstruction of 3D data; and design and implementation resources for hardware and software engineering projects. Dexela Limited was incorporated in 2003 and is based in London, the United Kingdom. It has an X-ray research and development facility in Sudbury, Massachusetts.
Usentric develops online proxy solution for brands in the retail, financial services and telecommunication industries. The company's products and services include secure payment online solutions, email protection, and secure ID. It is based in Sutton, U.K.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.
Inspiration Matters has developed a software and hardware system to drive high quality displays such as those used in car dealerships, estate agents and banks.
Wright Fenn provides medicine pills are manufactured and packaged in blister packs. For many patients, such as those in residential or care homes, hospitals or other institutions, these pills are repackaged by the pharmacy into dosage specific monthly packs to save nursing time and reduce dosage errors. Pharmaceutical licenses typically specify the form of the packaging and so it is expensive for the manufacturers to make and package pills in bulk form for pharmacies to repackage them into dosage specific packs. During 2003, pharmacists in the UK alone deblistered and repackaged approximately 70 million packs of pills ' mostly by hand. The number of patients requiring these patient specific packs is increasing each year at about 10-15%.
Kinomi
Seed Round in 2005
Kinomi provides a better way of automatically archiving and indexing email, both by subject matter, sender and receiver groups, and by reading content, which then enables people and organisations to retrieve relevant emails much more easily, if ever they are needed at some point in the future.
BioAnaLab Ltd.
Venture Round in 2005
BioAnaLab Ltd. is a services provider that specializes in the analysis of biologic drugs and vaccines. BioAnaLab was spun out of the University of Oxford in 2002 to meet the unique requirements of the biopharmaceutical industry. The Company helps its customers better understand the safety and efficacy of biologic drugs and vaccines by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market
By bridging the research to industry innovation gap, Water Innovate overcomes major obstacles that have existed in the water and environmental industries for too long. Water Innovate has assembled a technology pipeline that is transferring ground-breaking environmental technologies from research labs into the marketplace. Water Innovate clearly identifies and exploits routes to market by evaluating new technologies and investing significant resources in their development. A range of exciting technologies developed by leading experts in water and wastewater treatment are available. These can be viewed in our Product Datacentre by selecting the links on the left or the drop down menu on the right.
Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.
Inscentinel uses the exquisitely sensitive olfactory sense of bees to detect minute concentrations of volatile compounds such as explosives, drugs, or odours that indicate disease. The bees are held in a harness and can then be trained to recognize particular scents, in much the same way that sniffer dogs can be trained. In the presence of the odour for which they have been trained, the bees have a proboscis extension reflex, and this is then picked up by a camera and its associated software that then sends a signal to an operator or simply logs the data. A US patent has been granted and other patent applications are proceeding.
Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Diamond Hard Surfaces has developed a process to create amorphous diamond-like carbon coatings at lower temperatures (<50oC) and in thicker layers (up to 20 microns) than existing processes. Diamond Hard Surfaces coatings have the extreme surface characteristics of diamond such as low coefficient of friction and excellent wear properties. In addition, carbon is inert to almost everything and so is an excellent barrier against chemical corrosion.
Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Hardide is a family of low temperature CVD (chemical vapour deposition) Tungsten Carbide based coatings that increase the life of critical metal parts operating in abrasive, erosive, corrosive and chemically aggressive environments.
Invro is an electronic engineering company. Their focus is the efficient management of electrical energy by electronic means. It offers single earpiece radios, radio receiver sets, and FM radios. The company also provides high voltage power supplies for scientific and industrial applications; and instrumentation for power electronics applications.
Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.
Ciphergrid Ltd (previously Cipherware Ltd) has developed what it believes is a unique data access technology that, in its simplest form, enables enterprise applications (e.g. ERP, CRM, or stand alone applications such as MS Excel) to perform transactions with multiple, disparate, remote databases across the Internet in the same way (speed, functionality, security) as if the databases were local. Ciphergrid's uniqueness lies in the fact that it offers a reliably high transactional speed, that it is a 'plug & play' solution and that it offers significantly lower total cost of ownership than any alternative. Its built-in data encryption and security control mechanisms allow the use of the Internet instead of expensive, non scaleable, leased lines.
Telegesis is a supplier of wireless mesh networking modules based on Silicon Labs' technology.
Reviver Technologies
Seed Round in 2003
ReviveR Technologies Limited, (formerly known as PC Help Centre) is a UK based research and development company, which specialises in designing intelligent remote diagnostic tools for use within mission-critical PCs, servers and manufacturing control equipment. Today, ReviveR Technologies offer affordable diagnostic tools that provide advanced, yet simplified secure remote access, monitor and control management for mission-critical equipment 24/7/365. The essence of the technology is that a board or chip resides in a PC or server and reports back over the internet on the detailed status of the PC. If a fault develops, the fault is reported. If it cant be corrected remotely as is often possible with software faults, then an engineer is able to arrive with the necessary hardware module so that the fault may be fixed at a single visit.
Commerce Decisions delivers proven software – AWARD, best practice knowledge and expert services to assist sourcing projects through-life; from preparation, qualification, evaluation, negotiation to continuous supplier performance review and contract compliance. AWARD software provides a central web-based information and process & infrastructure enabling project teams to collaboratively make major contract decisions and monitor subsequent performance. It is proven to significantly increase contract value and reduce risk and used in projects totalling over £150 billion to date. AWARD is available in the UK via a number of routes, including CCS frameworks. Commerce Decisions customers include the Department for Transport, DWP, Defra, Transport for London, NHS, the UK Olympic Delivery Authority, the British Broadcasting Corporation, defence contractors and the UK and Finnish MOD.
Inscentinel uses the exquisitely sensitive olfactory sense of bees to detect minute concentrations of volatile compounds such as explosives, drugs, or odours that indicate disease. The bees are held in a harness and can then be trained to recognize particular scents, in much the same way that sniffer dogs can be trained. In the presence of the odour for which they have been trained, the bees have a proboscis extension reflex, and this is then picked up by a camera and its associated software that then sends a signal to an operator or simply logs the data. A US patent has been granted and other patent applications are proceeding.
Im-Pak Technologies
Seed Round in 2003
The Im-Pak technology has now been successfully demonstrated on three moulds, a water cup, a paint-can, and on a mould for a pre-form for PET bottles. In January 2006, Im-Pak agreed heads of terms by which a public company will take a licence for the Im-Pak process for use in certain market areas. At the time of writing, the deal has reached draft legal contract stage, and it is expected that the deal will be concluded in May. Im-Pak will receive both regular monthly payments, as advance royalties, plus two lump-sum payments, and will share in royalties generated by licensing the technology round the world. Im-Pak will continue to develop the technology for other applications.
Concurrent Thinking is based in Warwick, UK, and has a long heritage in the design and implementation of large-scale computing infrastructures and software for High Performance Computing. Our background provides us with a unique perspective on holistic approaches for system management and the design of scalable computing products that can meet the requirements of the next-generation data centre.
Provider of a technology platform intended to be used for customer data integration. The company's technology platform offers Customer Relationship Management (CRM) and enterprise integration services, enabling businesses to avail code-free integration and migration tools to make fully informed business decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.